We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

One World Lab, Tonbo Biosciences Partner

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Researchers now have access to a full resource of flow cytometry antibodies that are manufactured to the highest quality and precision, resulting in consistently high performance. In line with the One World Lab model, these antibodies are offered in test sized aliquots allowing researchers the flexibility to test multiple antibodies more cost efficiently.

OWL_005_Image.jpg

Conjugated primary antibodies are extremely useful reagents for studies in a number of scientific disciplines including analytical cytology, cell biology and molecular biology. They have high specificity and selectivity, and eliminate the need for a detection secondary antibody. Conjugated primary antibodies make exquisite tools in the identification of molecules that cannot be seen by the naked eye, and flow cytometry is one laboratory technique that relies upon such antibodies for multicolor protocols.

 Despite their importance, sourcing and validating antibodies for flow cytometry can be both costly and time-consuming which poses a huge challenge for end-users. However, the partnership between Tonbo Biosciences and One World Lab aims to change this. “I appreciate how the One World Lab business model is centered towards linking researchers and manufacturers,” said Robert Triulzi, Vice President, Operations of Tonbo Biosciences. “Ultimately the partnership with One World Lab will allow us to further strengthen the Tonbo Biosciences brand through customer reviews, and reach a wider customer base, by offering antibodies in test-size aliquots through this alternative distribution channel.”

To find your next primary antibody visit the further information link below.